What Analysts Recommend for AstraZeneca in December 2017
Wall Street analysts estimate AstraZeneca (AZN) will report earnings per share (or EPS) of $0.71 on revenues of $6.0 billion during 3Q17, 4.4% growth as compared to revenues of $5.7 billion during 3Q16....